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Subpart D of 45 C.F.R. § 46 provides additional protection for
children in research.' To determine whether pediatric research is
permissible, the regulations require a risk-benefit assessment of re-
search involving children. All children can participate in minimal risk
research.2 If there is the potential for direct benefit, then the potential
benefits must justify the risks. 3 If there is no potential for direct bene-
fit, children with a "disorder or condition" can participate if it entails
no more than a minor increase over minimal risk.4 Research that
seeks to enroll either (1) healthy children, but offers no prospect of
direct benefit and entails more than minimal risk; or (2) children with
a disorder or condition, but offers no prospect of direct benefit and
entails more than a minor increase over minimal risk, can be permitted
if, and only if, it is approved by a panel convened by the Secretary of
the Department of Health and Human Services (DHHS) pursuant to
45 C.F.R. § 46.407.5
In the more than two decades since passage of Subpart D, only
fourteen 407 panels have been convened.6 The first two were in the
t Dr. Lainie Ross is an associate professor, Department of Pediatrics and
assistant director, MacLean Center for Clinical Medical Ethics, University of Chi-
cago. Dr. Ross' research on children in research is funded by an NIH Grant (NLM I
G13 LM07472-01). The opinions expressed in this paper represents her own views,
and do not necessarily reflect the views of the NIH.
1 See Additional Protections for Children Involved as Subjects in Research,
48 Fed. Reg. 9814 (Mar. 8, 1983) (to be codified at 45 C.F.R. pt. 46), revised by
Federal Policy for the Protection of Human Subjects: Additional Protections for Chil-
dren Involved as Subjects in Research, 56 Fed. Reg. 28,302 (June 18, 1991) (to be
codified at 45 C.F.R. pt. 46).
2 Protection of Human Subjects, 45 C.F.R. § 46.404 (2004).
3 § 46.405.
4 § 46.406.
5 § 46.407 (providing an exception to C.F.R. §§ 46.404-.406).
6 Robert M. Nelson, A Brief History of Protocol Reviews under 45 CR
46.407. Presented at the American Society of Bioethics and Humanities, Oct. 2003,
Montreal, Can. A fourteenth protocol was reviewed in September 2004. See infra
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early 1990s. However, in 2002, Dr. Greg Koski, then director of the
Office for Human Research Protections (OHRP), stated that OHRP
had received over two dozen requests for 407 review in the previous
year,7 and from February 2001 through June 2003, eleven protocols
were reviewed.8 The impetus for 407 review may be due in part to
concerns of institutional reprisal if federal oversight were not sought.
In 1999 and 2000, a number of major universities were sanctioned by
the Office for the Protection of Research Risks (OPRR, now OHRP)
for failure of researchers and institutions to protect human subjects
adequately. 9
In this manuscript I provide a brief history of the first ten 407
panels, and then consider in more depth three of the last four review
panels.1° I conclude with several observations that can be gleaned
note 10.
7 Greg Koski, Remarks at the Meeting of the National Human Research
Protections Advisory Commission 48 (Jan. 29, 2002), available at
http://www.hhs.gov/ohrp/nhrpac/mtg0 1-02/0129NHR.txt.
8 Nelson, supra note 6. Dr. Nelson chaired all but one of the 407 panels.
9 See Lucio M. Guerrero & Robert C. Herguth, Human Tests Halted; U1C
Projects Suspended After Probe, CHI. SuN-TIMES, Aug. 28, 1999, at 1 (discussing the
sanctions against University of Illinois at Chicago in 1999); Philip J. Hilts, Safety
Concerns Halts Oklahoma Research, N.Y. TIMES, July 11, 2000, at F12; Philip J.
Hilts, US. Halts Human Research at Alabama, N.Y. TIMES, Jan. 22, 2000, at A12;
Philip J. Hilts, V.A. Hospital Is Told to Halt All Research, N.Y. TIMES, Mar. 29,
1999, at A25; Eric Hubler, FDA Move Halts Local Research: Thousands of Projects
Suspended at Six CU-Affiliated Institutions, DENV. POST, Sept. 24, 1999, at Al; and
Sheryl Gay Stolberg, Gene Therapy Ordered Halted at University, N.Y. TIMES, Jan.
22, 2000, at Al.
10 The most recent protocol, "Effects of Single Dose of Dextroamphetamine
in Attention Deficit Hyperactivity Disorder (ADHD): A Functional Magnetic Reso-
nance Study," was reviewed in September 2004. The protocol was different because
it involved the administration of a drug to healthy children and therefore both the
Food and Drug Administration (FDA) and OHRP participated in the 407 review. See
Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meet-
ing, 69 Fed. Reg. 47157 (Aug. 4, 2004).
The Panel that convened to discuss the research consisted of the Pediatric
Ethics Subcommittee of the Pediatric Advisory Committee of the FDA. This commit-
tee is a federal advisory committee (FAC) and therefore the meeting was open to the
public in contrast with all the other 407 panels which were not established as a FAC.
The pediatric ethics subcommittee recommended approval of the protocol with modi-
fications. For the consensus position of the committee (and not individual comments
from each panelist), see Summary of Minutes of the Pediatrics Ethics Subcommittee of
the Pediatrics Advisory Committee, at http://www.fda.gov/ohrms/dockets/
ac/04/minutes/2004-4066ml summary%20Minutes.pdf (Sept. 10, 2004). Neither the
committee's report nor its recommendations are publicly available on OHRP's web-
site (May 6, 2005). On March 2, 2005, however, OHRP received an e-mail request to
terminate the 407 review determination for this protocol, and OHRP complied. See
Memorandum to File from Kevin A. Prohaska, D.O., OHRP: Children's Research
(Vol. 15:401
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from a historical and ethical analysis of the 407 process: observations
that may be instructive for future 407 panels and for pediatric research
regulations more generally.
II. THE 1990s: THE FIRST TWO 407 PANELS
There is scant public information about the first two protocols,
except their reporting in the Federal Register. The first, "Myoblast
Transfer in Duchenne Muscular Dystrophy (DMD)" was denied ap-
proval in June 1991.11 There are no public records that explain why
the research was disapproved by the 407 panel. Despite this, at least
five human trials involving myoblast transfer were conducted in the
early 1990s.12 Four of the five studies found no improvement. 3 The
fifth claimed benefit, 14 but it has been widely discredited. 5 All these
studies involved boys (mid-childhood to adolescence) with DMD.
In order for a local institutional review board (IRB) to approve
this research, it would have to decide that the research either (1) had
the potential to provide direct benefit and the benefits justified the
risks; 16 or (2) had no potential to provide direct benefit, but the risks
Coordinator, 46.407 Review of Protocol Entitled "Effects of a Single Dose of Dextro-
amphetamine in Attention Deficit Hyperactivity Disorder" (May 16, 2005), at
http://www.hhs.gov/ohrp/panels/jreviewO1/withmemo.rtf (NIH withdraws request for
HHS 45 CFR 46.407 review). No explanation was provided.
Whether the 407 committee was different because it involved both OHRP
and the FDA; or whether it has set a new precedent is not known at this time. In light
of the lack of available documents and the other procedural unknowns, this protocol
and its review will not be considered further.
11 Proposed Protocol Entitled Myoblast Transfer in Duchenne Muscular
Dystrophy; Recommendations, 56 Fed. Reg. 49189 (Sept. 27, 1991).
12 Peter K. Law et al., Dystrophin Production Induced by Myoblast Transfer
Therapy in Duchenne Muscular Dystrophy, 336 LANCET 114 (1990) (describing the
first myoblast transfer study in humans); Emanuela Gussoni et al., Normal Dystrophin
Transcripts Detected in Duchenne Muscular Dystrophy Patients After Myoblast
Transplantation, 346 NATURE 435 (1992); J. Huard et al., Human Myoblast Trans-
plantation Between Immunohistocompatible Donors and Recipients Produces Im-
mune Reactions, 18 TRANSPLANTATION PROC. 3049 (1992); George Karpati et al.,
Myoblast Transfer in Duchenne Muscular Dystrophy, 34 ANNALS NEUROLOGY 8
(1993); Jerry R. Mendell et al., Myoblast Transfer in the Treatment of Duchenne's
Muscular Dystrophy, 333 NEw ENG. J. MED. 832 (1995).
13 See Gussoni et al., supra note 12, at 438; Huard et al., supra note 12, at
3051; Karpati et al., supra note 12, at 15; and Mendell et al., supra note 12, at 836.
14 See Law et al., supra note 12, at 114-15.
15 Eric P. Hoffman, Myoblast Transplantation: What's Going On?, 2 CELL
TRANSPLANTATION 49, 53-54 (1993); and Mildred Cho, In Reply to Misrepresentation
Conspires Against Potential Treatment for Muscular Dystrophy, IRB, Mar.-Apr.
1995, at 4, 6 (stating that the literature shows that myoblast transfer has yielded dis-
appointing results).
Protection of Human Subjects, 45 C.F.R. § 46.405 (2004).
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were either minimal 17 or a minor increase over minimal risk. 8  The
five studies were probably approved by their local IRBs under C.F.R.
§ 46.405 as the animal data may have suggested some potential for at
least transient benefit. 19 But to approve the study under C.F.R. §
46.405, the local IRB also needed to believe that the putative benefits
justified the risks. Given the lack of knowledge about stem
cell/precursor cell transfers, and the potential for immune rejection, a
benefit to risk ratio would have been difficult to quantify. It is also
not clear why, or how, a local IRB could have approved the first
myoblast transfer trials using children as subjects. In 1977, the Na-
tional Commission for the Protection of Human Subjects of Biomedi-
cal and Behavioral Research (National Commission) recommended
that children not be used in research if the scientific question could be
answered using adults,2° and the National Commission's reports are
the basis for most of our federal regulations on research protections.
The scientific goal of these studies was to understand the toxicity of
myoblast transfer. While adults with DMD may have been too weak
and less responsive to transplant, there are adults with Becker muscu-
lar dystrophy (a milder non-lethal form of muscular dystrophy) who
could have been the subjects of the initial studies.2'
The second 407 panel was convened to review research on "Cog-
nitive Function and Hypoglycemia in Children with IDDM [Insulin
Dependent Diabetes Mellitus, now known as Type I Diabetes]. 22
The study design involved both children with Type I Diabetes (a con-
dition) and healthy controls. The children would be asked to undergo
neurocognitive testing both at baseline and with low blood sugar (the
low blood sugar, or hypoglycemia, would be induced by an insulin
clamp technique). This technique involves infusing glucose and insu-
lin at varying infusion rates to attain a specific blood glucose level. It
involves the placement of two intravenous lines (one for the infusion
of glucose and insulin and one for blood glucose measurements). The
17 § 46.404.
IS § 46.406.
19 Peter Law, Beneficial Effects of Transplanting Normal Limb-Bud Mesen-
chyme into Dystrophic Mouse Muscles, 5 MUSCLE & NERVE 619, 626 (1982); P.K.
Law et al., Histoincompatible Myoblast Injection Improves Muscle Structure and
Function of Dystrophic Mice, 20 TRANSPLANTATION PROC. 1114 (Supp. 1988).
20 NAT'L COMM'N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL &
BEHAVIORAL RESEARCH, REPORT AND RECOMMENDATIONS: RESEARCH INVOLVING
CHILDREN, 2-4 (1977).
21 Mildred K. Cho, Are Clinical Trials of Cell Transplantation for Duchenne
Muscular Dystrophy Ethical?, IRB, Jan.-Apr. 1994, at 12, 14.
22 Cognitive Function and Hypoglycemia in Children with IDDM, 58 Fed.
Reg. 40819 (July 30, 1993).
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danger is miscalculation or an error in calibration, with the result of
severe hypoglycemia which can lead to seizures, coma, and even
death, although to date this procedure has been done on thousands of
volunteers without any serious adverse events.
Although there are no public records, it is clear that the IRB that
sought 407 review clearly believed that the research risks were more
than minimal or it could have approved the research locally under
C.F.R. § 46.404. If the research risks entailed a minor increase over
minimal risk, then the research could be approved for children with
diabetes (a condition), 23 but given the level of risk, the healthy chil-
dren could only serve as controls if the research were reviewed na-
tionally.24 If the research risks were found to entail more than a minor
increase over minimal risk, then the research would require national
review for both the children with diabetes and the healthy controls
25[C.F.R. § 46.407]. In speaking with the principal investigator, the
panel was convened only for the healthy controls.26 It was approved
by OPRR (now OHRP) in July 1993.
A literature search reveals that the insulin clamp technique, first
described in 1979,27 had been used in research studies in the 1980s
that enrolled not only children with diabetes but also healthy children
without 407 review. 28 In 2000, however, a research project using the
clamp technique was halted by OHRP because of concerns that the
study involved more than minimal risk, offered no prospect of direct
benefit, and enrolled healthy children without 407 review.29 The re-
searchers argued that their "healthy" children were obese, or were
children of obese parents, and therefore were at increased risk for de-
veloping diabetes, and therefore the research could qualify under
23 Protection of Human Subjects, 45 C.F.R. § 46.406 (2004).
24 § 46.407.
25 Id.
26 Interview with Dorothy Becker, M.D., Chief of Endocrinology and Diabe-
tes; Director, Diabetes Program at Children's Hospital of Pittsburgh; Professor of
Pediatrics, University of Pittsburgh School of Medicine, in Pittsburgh, PA (Oct.
2003).
27 Ralph A. DeFronzo et al., Glucose Clamp Technique: A Method for Quan-
tifying Insulin Secretion and Resistance, 237 AM. J. PHYSIOLOGY - ENDOCRINOLOGY
& METABOLISM 214, 216 (1979).
28 See Stephanie A. Amiel et al., Impaired Insulin Action in Puberty: A Con-
tributing Factor to Poor Glycemic Control in Adolescents with Diabetes, 315 NEW
ENG. J. MED. 215 (1986); and Silva Arslanian et al., Impact of Physical Fitness and
Glycemic Control on In Vivo Insulin Action in Adolescents With IDDM, 13 DIABETES
CARE 9, 10 (1990).
29 Eliot Marshall, Enforcers Halt NIH Study Called Less Risky than Outdoor
Play, 290 SCIENCE 1281 (2000).
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46.406.3o  OHRP accepted this explanation and the research re-
sumed.3 1 And yet, other healthy controls who are not at an increased
risk were enrolled, and continue to be enrolled, in clamp studies in
Minnesota.
32
III. RE-EMERGENCE OF 407 PANELS
Between August 2001 and June 2003, eleven 407 panels were as-
sembled.33 The panels included scientific, ethical, and regulatory ex-
perts and community representatives. The first seven panels were
convened in August 2001, and the panelists were promised anonymity
and submitted "unstructured" written reports shortly after the meeting.
The reports were unstructured in the sense that the panelists were not
given guidelines about what issues to consider.34  No votes were
taken. Of these seven protocols, three were retracted after the panels
met because they were found to be approvable under 45 C.F.R. §§
46.404-406, and two were withdrawn because they had closed enroll-
ment. OHRP produced a written summary of panel deliberations from
notes and individual reports of the other two. One of these studies
included using the insulin clamp technique with Japanese American
youth, who are considered at higher risk for developing
Type I diabetes, and their Caucasian cousins who would serve as con-
trols. It was approved and has been examined in detail elsewhere.35
30 Letter from Michael A. Carome, Director, Division of Compliance Over-
sight, to Michael M. Gottesman, Deputy Director for Intramural Research, National
Institutes of Health (Aug. 15, 2001), available at
http://www.hhs.gov/ohrp/detrm-letrs/aug0lo.pdf (describing the NICHD IRB review
on May 23, 2001). Elsewhere I argue in support of classifying "at risk" children as
having a "disorder or condition" for the purposes of classifying research under C.F.R.
§ 46.406. See Lainie Friedman Ross, In Defense of the Hopkins Lead Abatement
Studies, 30 J.L. MED. & ETHics 50, 52-53 (2002) (discussing what it means to have a
"disorder or condition" under § 46.406).
31 See Carome, supra note 30.
32 See Antoinette Moran et al., Insulin Resistance During Puberty: Results
from Clamp Studies in 357 Children, 48 DIABETES 2039 (1999) (discussing the results
of clamp studies on children with hypertension (who can be classified at increased
risk) and children with normal blood pressure (who are healthy controls)). Of note,
Moran et al. are working out of the University of Minnesota, which continues to
recruit healthy children for clamp studies. See UNIV. OF MINN., GENERAL CLINICAL
RESEARCH CENTER: PROTOCOL 488, at http://www.gcrc.umn.edu/gcrc/proto.php?p488
(last visited Feb. 9, 2005).
33 See Nelson supra note 6.
34 Id.
35 See generally Lainie Friedman Ross, Convening a 407 Panel for Research
Not Otherwise Approvable: "Precursors to Diabetes in Japanese American Youth" as
a Case Study, 14 KENNEDY INST. ETHics J. 165 (2004).
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The other study, "Alcohol, Sleep and Circadian Rhythms in Young
Humans, Study 2 - Effects of Evening Ingestion of Alcohol on Sleep,
Circadian Phase, and Performance as a Function of Parental History
of Alcohol Abuse/Dependence," also involved adolescents and adults.
The part of the grant requiring 407 review was a study that sought to
examine the effect of a moderate evening dose of alcohol on sleep and
waking performance in adolescents (aged fifteen and sixteen) and
young adults (aged twenty-one and twenty-two). In December 2003,
OHRP sent a letter to Rhode Island Hospital stating that the study was
disapproved and that the researchers should postpone the enrollment
of adolescents until the research has been performed in the adult sub-
population and the data analyzed.36 After the adult data is analyzed,
"re-review of the proposed research would be warranted., 37 This rec-
ommendation was consistent with the National Commission's position
to begin with adult subjects and only to enroll children-subjects if the
information is still needed as discussed above.38
In October 2002, a panel was convened to evaluate the ethics of a
research study on Dryvax (smallpox vaccine) in children. Although
the panel never physically met, they submitted individual signed re-
ports. The protocol was eventually withdrawn because bioterrorism
preparedness plans had evolved, such that diluted Dryvax in children
would not be used, and therefore there was no justification for the
particular clinical investigation to proceed.39
In May-June 2003, three additional panels met to review the fol-
lowing three protocols (1) "Characterization of mucus and mucins in
bronchoalveolar lavage fluids from infants with cystic fibrosis"; (2)
"Sleep Mechanisms in Children: Role of Metabolism"; and (3) "HIV
Replication and Thymopoiesis in Adolescents." The panelists were
asked to consider specific questions regarding risks and benefits, con-
sent, and other aspects of research ethics review. These structured,
signed (i.e., non-anonymized) reports were submitted to OHRP.
36 Letter from Irene Stith-Coleman, Director, Office for Human Research
Protections, to Kathryn Handshaw, Manager, Research Review Committees and
Communications, Rhode Island Hospital (Dec. 23, 2003), available at
http://www.hhs.gov/ohrp/children/407-Olpnl/lrih.pdf.
37 Letter from Acting Director, Office for Human Research Protections, to
Cristina V. Beato, Acting Assistant Secretary for Health 9 (Dec. 9, 2003), available at
http://www.hhs.gov/ohrp/children/407-Olpnl/cact.pdf describing deferral decision at
9.
38 See NAT'L COMM'N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL &
BEHAVIORAL RESEARCH, supra note 20; see also supra text accompanying note 20.
39 Letter from Irene Stith-Coleman, Office for Human Research Protections,
to Stewart Laidlaw, Director, Compliance Office, Harbor UCLA Medical Center (Jan.
24, 2003), available at http://www.hhs.gov/ohrp/dpanel/determ.pdf.
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Given the development and refinement of the process over the past 2.5
years, it is these three proposals and the expert panel reports that I
examine in depth. Relevant aspects of the protocols, IRB minutes,
communication with OHRP, and the individual panelist reports are
available on the OHRP web-site.4 °
IV. BRONCHOALVEOLAR LAVAGE FLUID FROM
INFANTS WITH CYSTIC FIBROSIS:
A. Study Description
Cystic Fibrosis (CF) is a genetic condition that presents with pul-
monary (lung) disease and gastrointestinal problems including me-
conium ileus (colonic obstruction) in the newborn, pancreatic insuffi-
ciency, and failure to thrive. The purpose of this study is to investigate
the initial pathogenesis of airway disease in CF. The researchers seek
to examine the relationship between hypothesized abnormalities in
airway surface liquid and chronic infection and inflammation. To do
this, the researchers propose performing three non-therapeutic bron-
choscopies (examination of the lower airways of the lung with a spe-
cial lens at the end of a long tube) and bronchoalveolar lavage (BAL).
Bronchoalveolar lavage involves inserting a thin tube through the
nose into the lungs (airways). A small amount of sterile salt water (2
teaspoonfuls) is placed into the airways through the tube, and then
suctioned out. The researchers propose to perform BAL three times
over a twelve month period on infants diagnosed prior to, or just after,
birth with CF (either because they have meconium ileus or a family
history that leads to early diagnosis), and to compare their data with
control data from children without CF who are undergoing BAL for
clinical indications.
Two parent consent is sought for the children with CF who will
undergo the BAL for research purposes. No assent is sought because
the children are too young. The children will be paid $100 for each
bronchoscopy and a $50 bonus if they undergo all three (total of
$350). The parents will be paid $50 for filling out a questionnaire at
the time of the child's bronchoscopy and a $50 bonus for the comple-
tion of the study (total of $200).
Although the researchers tried to suggest that there was some pos-
sible benefit to the individual children, the University of North Caro-
40 U.S. DEP'T HEALTH & HUMAN SERVS., OFFICE FOR HUMAN RESEARCH
PROTECTIONS, SPECIAL PROTECTION FOR CHILDREN AS RESEARCH PARTICIPANTS, at
http://www.hhs.gov/ohrp/children/ (last visited Feb. 10, 2005).
[Vol. 15:401
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lina (UNC) IRB argued that the research exposed children with a con-
dition to more than a minor increase over minimal risk without the
prospect of direct therapeutic benefit and suggested that the research
could only be done with a 407 review.
B. Ethical Issues
All of the 407 panel members agreed that the research could po-
tentially yield important generalizable information, and that the re-
search did not offer the prospect of direct benefit. They also agreed
that the research needed to be done on children, as no adequate animal
model exists and most individuals with CF are symptomatic by one
year of age. This may or may not be scientifically accurate. A review
article in 2001 describes eleven different mouse models of CF, 4 1 in-
cluding one that is studying "the role of CFTR [the gene] in determin-
ing either the volume or the ionic concentration of the ASL [airway
surface lining] in the lung epithelia. ' '42 The review also notes that
"[a]ll these potential influences, and others (e.g., the role and distribu-
tion of submucosal glands) can be controlled for, and altered, in future
studies.' ' 3 These are some of the factors that this study seeks to exam-
ine in infants. Thus, although expert number five was convinced that
the question: "Why children now?" could be justified,44 it could be
argued that the research team needs to explain whether advances in
animal models should be pursued further before using this most vul-
nerable population (infants with a life-threatening condition) in inva-
sive research.
The panel members raised two methodological questions regard-
ing the protocol. The first was the need for greater clarification about
sedation. The second was whether at least one of the bronchoscopies
could be piggy-backed onto clinical care. The panel members agreed
that the research risks to the control children was negligible given that
the children would be undergoing BAL for clinical indications and
could be approved under 45 C.F.R. § 46.404. To minimize the risks
to the children-subjects with CF, the panelists asked the researchers to
propose time-frame windows, rather than specific dates, during which
41 Donald J. Davidson & Mark Rolfe, Mouse Models of Cystic Fibrosis, 17
TRENDS GENETICS S29 (Supp. 2001).
42 Id. at S35.
43 Id.
44 Mary Faith Marshall, Panel Review of Research Involving Children Under
Subpart D: "Characteristics of Mucus and Mucins in Broncheolar Lavage Fluids




each bronchoscopy needed to be done to possibly allow one or more
of the BAL samples to be collected simultaneous with clinical care
(e.g., if the infants were to undergo a bronchoscopy or intubation dur-
ing that time period).
As currently designed, the panel members disagreed as to the
level of risk that three non-therapeutic bronchoscopies would pose to
infants with CF. Two panelists thought that given the experience of
the researchers at UNC, the risks could be classified as a minor in-
crease over minimal risk and that the research could be approved un-
der C.F.R. § 46.406. Four of six panelists, however, thought that
three bronchoscopies performed under sedation when there was no
clinical indication to do so otherwise, constituted more than a minor
increase over- minimal risk which would require 407 review. Never-
theless, a literature review reveals that performing BAL without clini-
cal indications has been a part of pediatric research throughout the
world for years,45 without 407 review for those done in the U.S.
4 6
Like the myoblast transfer research and the insulin clamp studies a
decade earlier, this is further evidence that there is wide variation in
interpreting what a minor increase over minimal risk entails.
Some concern was raised by panel members regarding the consent
process. Two panelists expressed the need for a separation between
the clinician caring for the child and the investigator who presents the
research opportunity to avoid both parental perception of undue pres-
sure to enroll and parental misperception of therapeutic benefit. This
is particularly important given the vulnerability of families with
young children with a life-threatening condition.
Concerns were also raised about costs and payments. Several
panelists were concerned that in the event of research-related injury,
the consent form stated that the investigators would assist in obtaining
appropriate medical treatment, but the cost would be borne by the
family. As one panelist (number five) noted: "Although compensa-
tion for research injury is not required by regulation, virtually all fed-
eral human research advisory committees have recognized it as a
45 David S. Armstrong et al., Lower Respiratory Infection and Inflammation
in Infants with Newly Diagnosed Cystic Fibrosis, 310 BRIT. MED. J. 1571 (1995);
Carolyn J. Dakin et al., Inflammation, Infection, and Pulmonary Function in Infants
and Young Children with Cystic Fibrosis, 165 AM. J. RESPIRATORY & CRITICAL CARE
MED. 904 (2002); G.M. Nixon et al., Early Airway Infection, Inflammation, and Lung
Function in Cystic Fibrosis, 87 ARCHIVES DISEASE CHILDHOOD 306 (2002); Jane L.
Bums et al., Longitudinal Assessment of Pseudomonas Aeruginosa in Young Children
with Cystic Fibrosis, 183 J. INFECTIOUS DISEASES 444 (2001); and K. Balough et al.,
The Relationship Between Infection and Inflammation in the Early Stages of Lung
Disease from Cystic Fibrosis, 20 PEDIATRIC PULMONOLOGY 63 (1995).
46 Burns et al., supra note 45, at 444; Balough et al., supra note 45.
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moral duty owed by the sponsors of the research. 4 7 A second con-
cern was about the payments. If the infants completed all three bron-
choscopies, the children would earn $350, the parents $200 which
included a bonus payment. While one could argue that research in
children should never offer any financial inducements beyond "token
gestures" and reimbursement for the actual expenses incurred by the
families (e.g., parking),48 the panelists appeared to be comfortable that
the amount of money was commensurate with the inconveniences
(parental time and child discomfort) that the families were being
asked to undergo. There was some uneasiness, however, regarding
the bonus.
Despite these concerns, the expert panelists unanimously agreed
that the research could offer important generalizable knowledge and
approved the research. In June 2004, OHRP sent out a determination
letter approving the research under C.F.R. § 46.407 and requiring a
number of revisions as recommended by the 407 panel.49 OHRP has
not yet given final approval for this project to proceed.
V. SLEEP MECHANISMS IN CHILDREN
A. Study Description
The purpose of this study is to measure metabolic function of ado-
lescent children cycling in wakefulness and sleep using nuclear mag-
netic resonance (MR) spectroscopy. The researchers also propose to
study a subset of children in the same way, except after sleep depriva-
tion. Their ultimate goal is to study all age groups, as it is known that
the sleep processes of children and adults are different, but in this
research project, they will start with five adults and then focus on ado-
lescents aged thirteen to seventeen years.
The research entails three sessions. The first involves a complete
medical history, physical exam, and blood and urine tests. The next
two sessions involve admission to the clinical research center of the
47 Marshall, supra note 44.
48 See, e.g., INST. OF MED. ETHICS, MEDICAL RESEARCH WITH CHILDREN:
ETHiCS, LAW AND PRACTICE 204-05 (Richard H. Nicholson ed., 1986) (discussing the
financial implications involved in child-focused research studies); and Am. Acad. of
Pediatrics Comm. on Drugs, Guidelines for the Ethical Conduct of Studies to Evalu-
ate Drugs in Pediatric Populations, 95 PEDIATRICS 286, 293 (1995) (providing ethical
guidelines for the inclusion of children in drug studies).
49 Letter from Bernard A. Schwetz, Director, Office of Human Research
Protections, to Stephen A. Bernard, Chairman, Committee on the Protection of the
Rights of Human Subjects, University of North Carolina at Chapel Hill School of
Medicine (June 4, 2004), available at http://www.hhs.gov/ohrp/children/fund2.pdf.
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hospital for duration of between twenty-four and fifty-six hours. The
first night entails polysomnography to exclude undiagnosed sleep
disorders. During the hospital admissions, two intravenous lines are
placed - one for infusions of 13C-acetate or 13C-glucose, and the other
for blood sampling for up to twelve hours, and MR studies lasting up
to ninety minutes. One group receiving acetate and glucose will be
studied after normal activities; the other after fifty-two hours of sleep
deprivation. The adolescent will be paid up to $100 and the parent(s)
up to $350. One parent consent and the adolescent's assent are
sought. Although the researchers describe the risks as minimal in the
consent form, however, the Einstein Committee on Clinical Investiga-
tions found it to involve more than minimal risk. Since the research is
proposed on healthy adolescents, the IRB requested 407 review.
B. Ethical Issues
In this case, all of the expert panelists agreed that the risks were
more than minimal and that the subjects were healthy. The main issue
for the 407 panel was the decision to enroll children when the re-
searchers explained in the grant application that "[n]one of the studies
proposed have been done in adults or children. Indeed, only a small
part of what is proposed here has been done in animals with the use of
invasive techniques. '50 The researchers chose to begin with children
at least in part because the NIH grant proposal was written in response
to a grant request for application (RFA) that stipulated the inclusion of
adolescent subjects.5'
The primary reason to do research using a novel invasive tech-
nique on adults first is to ensure safety. If the adult data are sufficient
to answer the research question then the research need not enroll chil-
dren. If the adult data show greater safety risks or less therapeutic
value than was anticipated, then the benefit to risk calculation changes
and the research may now be unapprovable in pediatrics. While the
researchers give adequate reasons to show that they will need to enroll
children to answer their research questions, they do not give any ar-
guments to justify why children should be the first subjects. One pan-
elist believed five adult subjects were adequate to ensure safety,
50 Albert Einstein Coll. of Med. of Yeshiva Univ.: Comm. on Clinical Inves-
tigations, Drug, Device, and Gene Transfer/Gene Therapy Human Subject Research
Protocol Application, Sleep Mechanisms in Children: Role of Metabolism, 1 (submit-
ted by Gabriel G. Haddad, Principal Investigator), available at
http://www.hhs.gov/ohrp/panels/407-03pnl/pappl.pdf (last visited Feb. 10, 2005).
51 NAT'L INST. OF HEALTH GUIDE, RFA: HL-01-006, SLEEP AND SLEEP
DISORDERS IN CHILDREN (June 6, 2001), available at http://grants.nih.gov/grants/
guide/rfa-files/RFA-HL-01-006.html.
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whereas another panelist was not sure and asked for review by a data
safety monitoring board (DSMB) before enrolling adolescents. A
third panelist felt that knowledge about the adult subjects would not
make the technique safer and therefore did not see the lack of adult
data as problematic. The other two panelists felt that greater studies
in adults were needed first. They expressed two concerns: (1) the
safety of the MR spectroscopy - not in the amount of radiation, but in
its performance while using polysomnography (concern that the wires
could become heated during the study that could take as long as ninety
minutes); and (2) the tolerance of sleep deprivation. Since some
adults are to be recruited, the two panelists argued that they should
undergo the procedure first so as to better clarify the known risks and
to potentially unveil other unanticipated risks.
There was also concern regarding the payment. As stated in the
protocol, the parents would receive more money than the adolescent
even though only the adolescent would undergo the procedures. While
one panelist was able to justify this on the grounds that money may
have greater "undue influence" on adolescents who have fewer oppor-
tunities to earn money, the others were concerned that this would lead
to parental pressure to participate and to remain in the study, even if
the adolescent wanted to withdraw. This is made even more problem-
atic by the consent document which describes payment before stating
the risks and benefits of the research.
Another issue is consent. Although not raised by the panelists, the
consent forms only seek one parent's permission. The federal regula-
tions allow IRBs to decide whether one or two parent consent is
needed for research classified under C.F.R. § 46.404 and C.F.R. §
46.405, but research covered under C.F.R. § 46.406 and C.F.R. §
46.407 require permission of both parents. 52 Whether the second par-
ent's consent adds much in a culture in which almost of half of chil-
dren will spend at least part of their childhood in a single parent home
is debatable. In this case, however, a large amount of money is being
offered to the parents. If one believes that two parents would place
additional pressure on the adolescent to participate, then the second
parent's permission offers no protection. If one believes that by seek-
ing the permission of both parents, one parent might look beyond his
or her self-interest and focus on the child's best interest, then the sec-
ond parent's permission may offer protection. There are no data.
However, whether the second parent's consent provides additional
protection cannot, and should not, be solved at the individual protocol
level, but would require a revision of the regulations.
52 Protection of Human Subjects, 45 C.F.R. § 46.408(b) (2004).
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The panelists also expressed concern about how the researchers
would exclude adolescents with a history of infection, hepatitis, drug
abuse, or pregnancy. It is unclear whether this information will be
obtained only by history (as suggested in the protocol) or by blood or
urine testing (to be performed at the first visit). If determined through
blood or urine testing, the consent should describe this explicitly and
discuss how and to whom such information will be disclosed.
Although no vote was taken, at least two, if not three, of the five
panelists recommended against approving this research (one panelist
was willing to consider approval after a DSMB reviewed the safety of
the research done on adults). In March 2004, OHRP concluded that
the studies on children should be disapproved until the adult data were
collected and analyzed.5 3 To date the adult data have not been pre-
sented to OHRP for re-consideration.
VI. HIV REPLICATION AND THYMOPOIESIS IN
ADOLESCENTS:
A. Study Description
The purpose of the study is to examine several aspects of the
function of the thymus (an organ that plays a key role in the body's
defense against infection and cancer) in subjects aged thirteen to
twenty-four years who acquire HIV at birth, versus subjects who ac-
quire HIV through sexual activity or drug abuse, versus subjects who
are HIV-negative. All of the potential subjects are followed at the
University of California at Los Angeles (UCLA) hospitals. All would
undergo medical histories and physical exams as well as computed
tomography (CT) exams of the thymus.
The researchers seek to include a sub-study in their research in
which the subjects are given deuterium (heavy water) labeled glucose
over twenty-four hours, either intravenously or by mouth during a
twenty-four hour stay in the General Clinical Research Center, and to
continue to take heavy sugar water by mouth over the next month. If
the subjects are over eighteen years, they will consent or refuse to
participate themselves. Otherwise, the researchers will seek one-
parent consent and the assent of the child For participation in the
sub-study, the subjects will be paid seventy-five dollars for the over-
53 Letter from Bernard A. Schwetz, Acting Director, Office of Human Re-
search Protections, to Chester M. Edelmann, Jr., Chairman, Committee on Clinical
Investigation, Albert Einstein College of Medicine of Yeshiva University (Mar. 23,
2004), available at http://www.hhs.gov/ohrp/children/407-03pnl/hhhsdet.pdf.
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night stay and thirty-five dollars twice for the two blood collections
that seek to examine the amount of labeled glucose that enters their
white blood cells. The UCLA IRB thought that the research could
answer an important research question, but they thought it posed more
than a minor increase over minimal risk in a healthy (HIV-negative)
population, and could not be approved without 407 review.
B. Ethical Issues
Although the UCLA IRB was mainly concerned about the risks in
the sub-study,54 the 407 panelists were more concerned about radia-
tion exposure from the non-contrast spiral CT of the thymus which
was being proposed to measure the gland's volume. This involves
radiation exposure to a gland that is known to be sensitive to radia-
tion.55 Although the amount of radiation is low, there is debate as to
whether even this amount of radiation may increase the risk of can-
cer.56 The main study also includes Tanner staging, which is the de-
termination of the level of sexual development in adolescents from
stage I (pre-pubescent) to stage V (mature adult phenotype). While
Tanner staging is not physically risky or invasive, some adolescents
may find the process more stressful than one might anticipate.57 This
issue was not raised by the UCLA IRB, nor any of the 407 panelists.
The panelists concurred that the study and sub-study did not offer
the prospect of direct benefit. Some panelists believed the research
involved no more than minimal risk and suggested that the research be
approved under C.F.R. § 46.404. The others believed it involved at
most a minor increase over minimal risk such that the enrollment of
HIV-positive adolescents could be approved under C.F.R. § 46.406,
but that the enrollment of healthy controls would require national re-
view.58 One panelist considered whether the HIV-negative controls
could be considered "at risk for having a condition" (expert number
54 Letter from Steven Peckman, Associate Director, Human Subjects Re-
search, University of California Los Angeles, to Michael Carome, Director, Office for
Human Research Protections, Department of Health and Human Services (July 22,
2002), available at http://www.hhs.gov/ohrp/panels/407-O4pnl/review.htm (request-
ing review of research under § 407 by a panel of experts convened by the HHS Secre-
tary).
55 Donald P. Frush et al., Computed Tomography and Radiation Risks: What
Pediatric Health Care Providers Should Know, 112 PEDIATRICS 951, 952 (2003).
56 Id.
57 Anne Marie McCarthy et al., Psychological Screening of Children for
Participation in Nontherapeutic Invasive Research, 155 ARCHIVES PEDIATRICS &
ADOLESCENT MED. 1197 (2001).
58 Protection of Human Subjects, 45 C.F.R. § 46.407 (2004).
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seven). 59  The researchers stated that they will recruit the HIV-
negative adolescents from their HIV clinic. These adolescents and
young adults are being followed because of their high risk activities.
If these "at risk" adolescents are included in the category of children
having a disorder or condition (like the obese children in the diabetes
study60), then even those panelists who thought that the research in-
volved a minor increase over minimal risk could approve the research
under C.F.R. § 46.406 without the need for 407 review.
Another important issue is that of consent. Again, the researchers
seek the adolescent's assent and permission from only one parent,
despite the requirement in the federal regulations for two-parent per-
mission for research covered under C.F.R. § 46.407 "unless one par-
ent is deceased, unknown, incompetent, or not reasonably available,
or when only one parent has legal responsibility for the care and cus-
tody of the child.",
61
Two other consent issues were also raised. First, concern was ex-
pressed regarding the possibility that a subject would be found to be
pregnant, and her right to confidentiality. Clearly this needs to be
addressed in the consent form and in the consent process. Second,
some of the adolescents will become eighteen years of age during the
course of the study, and they should consent for continued participa-
tion for themselves.
In summary, four of the eight expert panelists believed that both
the HIV main study and the sub-study entailed at most minimal risk
and could be approved as C.F.R. § 46.404. The others believed that
the risk was a minor increase over minimal risk, such that the research
on the HIV-positive adolescents could be approved under C.F.R. §
46.406, but that 407 review was needed for the HIV-negative patients.
If a broader interpretation of "condition" were adopted, one could
argue that adolescents at "high risk" for HIV should be considered
within the purview of "adolescents with a disorder or condition," and
the research could be approved under C.F.R. § 46.406 for all the sub-
jects. However, in March 2004, OHRP approved this research project
with modifications under C.F.R. § 46.407,62 which means that the "at
59 Letter from Rosemary B. Quigley, Center for Medical Ethics and Health
Policy, Baylor College of Medicine to Bernard A. Schwetz, Acting Director, Office
for Human Research Protections, Department of Health and Human Services 2 (June
27, 2003), available at http://www.hhs.gov/ohrp/panels/407-O4pnl/exp7.htm.60 See supra text accompanying notes 30-31.
61 § 46.408(b).
62 Letter from Bernard A. Schwetz, Acting Director, Office for Human Re-
search Protections, Department of Health and Human Services, to Robert A. Figlin,
Chairman, Medical Institutional Review Board, Office for Protection of Research
Subjects, University of California Los Angeles (Mar. 23, 2004), available at
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risk HIV-negative" controls were not considered to have a condition
relevant to the research. In December 2004, OHRP found all the
stipulations were addressed and stated that the research could pro-
ceed.63
VII. LESSONS LEARNED
The first observation is the evolution in the 407 process since the
first cases in the 1990s. The federal regulations do not provide guid-
ance about the structure or process for 407 panels. The decision to
make a number of documents available to the public, including rele-
vant parts of the research protocol; the communication between
OHRP and the institution that requested the review; and the comments
of the expert panelists are important because they introduce greater
transparency into the process. Transparency is valuable because it
can help reduce referrals by IRBs of protocols that do not fit the crite-
ria for such review.64 Transparency may also promote greater referral
to the 407 process by institutions in which research is being done that
requires 407 review. Robert Nelson, the chair of virtually all of the
recent 407 panels, recommended that these panels become a Federal
Advisory Committee (FAC),65 which are required to be open to the
public. The recent Institute of Medicine (IOM) report also recom-
mended a standing committee because a continuing panel would ac-
cumulate experience and insight.66 In March 2004, the Secretary's
Advisory Committee on Human Research Protections (SACHRP),
established after the National Human Research Protections Advisory
http://www.hhs.gov/ohrp/panels/407-04pnl/khhsdet.pdf.
63 Letter from Bernard A. Schwetz, Director, Office for Human Research
Protections, Department of Health and Human Services, to Paul A Krogstad, David
Geffen School of Medicine (Dec. 24, 2004), available at http://www.hhs.gov/ohrp/
children/kronstadfinal.pdf.
64 COMM. ON CLINICAL RESEARCH INVOLVING CHILDREN, BD. ON HEALTH
SCIENCES POLICY, INST. OF MED. OF THE NAT'L ACAD., ETHICAL CONDUCT OF
CLINICAL RESEARCH INVOLVING CHILDREN 272-73 (Marilyn J. Field & Richard E.
Behrman eds., 2004) (discussing the benefits of the OHRP's § 407 process and poten-
tial improvements).
65 Robert M. Nelson, Comments on OHRP Announcement of 407 Review
Panel, INSTITUTIONAL REV. BOARD - DISCUSSION & NEWS FORUM, Aug. 23, 2002,
available at http://www.irbforum.org/forum/read/3/10181 / 10181 Vt.
The panel that met in September 2004 regarding Dextroamphetamine in
healthy children was a FAC because it consisted in part of the Pediatric Ethics Sub-
committee of the Pediatric Advisory Committee of the FDA which is a FAC (see
supra note 10).
66 COMM. ON CLINICAL RESEARCH INVOLVING CHILDREN, BD. ON HEALTH
SCIENCES POLICY, INST. OF MED. OF THE NAT'L ACAD., supra note 64 at 272-73.
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Committee (NHRPAC) was disbanded, endorsed a non-FAC open
panel model. 6
And yet, while the process has evolved, the issues raised have not
changed. Two 407 panels, one convened in 199368 and one in 200169
examined the risks of the insulin clamp technique on healthy children.
Although each protocol was approved by its 407 panel, one cannot
deduce that the insulin clamp technique is always approvable in
healthy children because it entails more than minimal risk (two intra-
venous lines and the infusions of glucose and insulin which can lead
to the potentially small, but possible, risk of severe hypoglycemia).
However, one could imagine techniques or innovative procedures for
which the level of risk decreased with familiarity such that later stud-
ies using them would not require 407 review.
A second observation from the 407 process is the wide variability
between panelists about the level of risk these protocols entail, a vari-
ability previously documented reported between pediatric chairper-
sons and between IRB chairpersons. 7 1 NHRPAC attempted to pro-
vide greater detail regarding which procedures should be judged to
belong to each of the three categories of risk, 2 but NHRPAC was
disbanded before its suggestions were debated and adopted. The LOM
committee also examined the categories of risk and concluded that
SACHRP "should be encouraged to continue its predecessor's work to
develop consensus assessments about the risk of common research
procedures. 73
By publishing the expert panel reports, IRB members, researchers,
and the public at large can comment on the panelists' recommendation
regarding risk classification. This is particularly important in the
studies in which there was wide variability on the level of risk that the
research entailed. Dialogue may lead to a body of cases described as
67 SEC'Y ADVISORY COMM. ON HUMAN RESEARCH PROTECTIONS, SUMMARY
MINUTES 4-5 (Mar. 29-30, 2004), available at http://www.hhs.gov/ohrp/sachrp/
mtgings/mtg03-04/min0329.pdf.
68 Cognitive Function and Hypoglycemia in Children with IDDM, 58 Fed.
Reg. 40819 (July 30, 1993).
69 See U.S. DEP'T OF HEALTH AND HUMAN SERV., supra note 40.
70 Jeffrey Janofsky & Barbara Starfield, Assessment of Risk in Research on
Children, 98 J. PEDIATRICS 842, 843 (1981).
71 Seema Shah et al., How do Institutional Review Boards Apply the Federal
Risk and Benefit Standards for Pediatric Research?, 291 JAMA 476 (2004).
72 NAT'L HUMAN RESEARCH PROT. ADVISORY COMM. REP., CLARIFYING
SPECIFIC PORTIONS OF 45 CFR 46 SUBPART D THAT GOVERNS CHILDREN'S RESEARCH
1, available at http://www.hhs.gov/ohrp/nhrpac/documents/nhrpac l6.pdf.
73 COMM. ON CLINICAL RESEARCH INVOLVING CHILDREN, BD. ON HEALTH
SCIENCES POLICY, INST. OF MED. OF THE NAT'L ACAD., supra note 64 at 135.
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minimal risk, a minor increase over minimal risk, and more than a
minor increase over minimal risk. The data could serve as guidance
for other IRBs about how such research is being classified by compa-
rable institutions, and will provide a forum when serious disagree-
ments arise. It would be a democratic and transparent approach to
guideline development. In fact, it would be useful if OHRP decided
to make publicly available all protocols that it receives for 407 review,
even those in which the 407 referral is voided, to give further guid-
ance to IRBs about what research can be approved at the local level.
A third observation is that the research projects under review had
already received federal funding. This means that they had been peer-
reviewed and found to have significant scientific merit, but that they
may not have been reviewed for their research ethics standard. While
IRB review earlier in the process would avoid the delay that a 407
panel generates, it significantly increases the workload of IRBs by
requiring review of many projects that are not funded and therefore
not executed. An alternate mechanism to avoid funding ethically un-
approvable research would be for scientific review panels to system-
atically include ethicists who could seriously evaluate the research
ethics component of the grant application, and encourage the review
panel to take the research ethics issues into consideration in their
funding decisions. This is important because research designs are
dependent on the current state of knowledge, such that a delay of two
or three years may make the research questions obsolete, and yet the
funding mechanism might not permit or encourage revision of the
research design. A cumbersome process, then, will discourage re-
searchers and their institutions from applying for 407 review, and may
lead institutions to employ an overly liberal interpretation of minimal
risk, or a minor increase over minimal risk, in order to justify approv-
ing a research project, particularly one that is externally funded.
A fourth observation is that despite IRB and expert panel review,
two of the consent forms sought the consent of only one parent, al-
though the federal regulations require two parent consent for all re-
search reviewed under 407. This may have been an oversight, or it
may have been the belief that the second parent would not add much
protection. This suggests that, at minimum, the current policy should
be re-examined.
A fifth observation is the issue of payment. Payment was offered
in all three studies. The studies varied in how much was paid to the
child versus the parent, as well as the actual amount paid. This topic
is not addressed in the federal regulations. Although discouraged by
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the American Academy of Pediatrics,74 it is not prohibited in the
United States and has found some ethical support. 75 The public proc-
ess may help create guidelines by community consensus regarding its
legitimacy, and if legitimate, how much children and their parents
should be paid. There was also some discussion regarding compensa-
tion for injury, another topic not addressed in the federal regulations.
Many ethics advisory panels have supported the proposition to com-
pensate all research subjects injured directly by their research partici-
pation.76 This may be even more justified for research requiring a 407
review.
VIII. RECOMMENDATIONS
Some important research questions on children will entail more
than a minor increase over minimal risk and not offer the prospect of
direct benefit. While an Institute of Medical Ethics working group
(UK) concluded that such research should never be performed,77 the
National Commission (US) voted to permit such research (with two
commissioners dissenting). 78 The concurring commissioners argued
that such research should be permitted but restricted in its use.79 They
also argued for national review to ensure greater scrutiny of both the
scientific merit and the ethical concerns. 80  While 407 panels can of-
fer this additional scrutiny, I have tried to show that the current struc-
ture needs reform. The panelists cannot vote, nor attempt to achieve
consensus, lest they act as a committee without authority to do so.
8 1
74 Am. Acad. of Pediatrics Comm. on Drugs, supra note 48, at 289.
75 COMM. ON CLINICAL RESEARCH INVOLVING CHILDREN, BD. ON HEALTH
SCIENCES POLICY, INST. OF MED. OF THE NAT'L ACAD., supra note 64 at 225-26;
Lainie Friedman Ross, Payment in Pediatric Research, 9 DETROIT J.L. & MED. 1
(2005).
76 See, e.g., PRESIDENT'S COMM'N FOR THE STUDY OF ETHICAL PROBLEMS IN
MED. & BIOMEDICAL RESEARCH, COMPENSATING FOR RESEARCH INJURIES: A REPORT
ON THE ETHICAL AND LEGAL IMPLICATIONS OF PROGRAMS TO REDRESS INJURIES
CAUSED BY BIOMEDICAL AND BEHAVIORAL RESEARCH (1982); ADVISORY COMM. ON
HUMAN RADIATION EXPERIMENTS, FINAL REPORT 774 (1995); COMM. ON ASSESSING
THE SYS. FOR PROTECTING HUMAN RESEARCH PARTICIPANTS, INST. OF MED. OF THE
NAT'L ACAD., RESPONSIBLE RESEARCH: A SYSTEMS APPROACH TO PROTECTING
RESEARCH PARTICIPANTS 193-94 (Daniel D. Federman et al. eds., The National Acad-
emies Press 2003); and COMM. ON CLINICAL RESEARCH INVOLVING CHILDREN, BD. ON
HEALTH SCIENCES POLICY, INST. OF MED. OF THE NAT'L ACAD., supra note 64, at 227.
77 INST. OF MED. ETHICS, supra note 48, at 234.
78 NAT'L COMM'N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, supra note 20, at 139.
79 Id. at 139-41.
go Id.
81 Robert M. Nelson et. al., Pediatric Testing: The Process of Federal Panel
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Although public comments are solicited by OHRP as required for
research to be approved under C.F.R. § 46.407, the public can only
attend and participate if the panel is convened as a FAC. While a
standing panel may resolve many of the procedural problems, it will
not necessarily resolve all of the substantive problems such as: (1)
Whether all research approved under C.F.R. § 46.407 ought to require
two parent consent; (2) Whether payment to children or parents be-
yond reimbursement is morally legitimate; and (3) Whether research
approved under C.F.R. § 46.407 should be required to have an injury
compensation plan. The questions raised by the 407 process may help
elucidate how the regulations should be revised for research that is
classified under C.F.R. § 46.407 as well as research involving children
more generally.
Review of Research Protocols Involving Children, I MED. RES. LAW & POL'Y 613
(2002).
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